ctDNA Methylation Sequencing
More and more studies have been proved the usefulness of quantitative and qualitative ctDNA methylation as diagnostic, prognostic, and monitoring markers in patients with cancer. With extensive expertise in ctDNA methylation sequencing and analysis as well as unparalleled sequencing technologies, Creative Biolabs supports one-stop ctDNA methylation sequencing and analysis services from ctDNA extraction, library preparation, sequencing to data analysis.
ctDNA Methylation in Cancer
ctDNA is tumor-derived fragmented DNA in the cell-free fraction of the blood. It carries tumor-specific genetic and epigenetic mutations and can be used as an alternative source of tumor DNA in cancer diagnosis and prognosis. Compared with somatic mutation analysis, ctDNA methylation profiling has several advantages for tumor detection, such as multiple detectable methylation target regions, multiple altered CpG sites within each targeted genomic region, and higher clinical sensitivity and dynamic range. Besides, ctDNA methylation profiling provides two main advantages for tumor detection over other ctDNA mutations and rearrangements. Firstly, ctDNA methylation may be detectable at an early stage in carcinogenesis. Secondly, ctDNA methylation profiling helps to determine the origin of malignancy. Although increasing studies have revealed ctDNA methylation is a useful biomarker for early diagnosis, prognosis prediction, and screening for many types of cancer such as lung cancer, colorectal cancer (CRC), and gastric cancer, it also requires more large-scale investigations to validate clinical applicability.
Fig.1 cfDNA methylation analysis for CRC diagnosis. (Luo, 2020)
Our Capacities
Creative Biolabs is a world-leading services provider in the field of ctDNA methylation sequencing and analysis. Our state-of-the-art facilities and highly qualified scientific team allow us to deliver ctDNA methylation sequencing and analysis services with unparalleled quality and excellence. Our service package includes ctDNA extraction, library preparation, high-through sequencing, and data analysis. Creative Biolabs’ unique ctDNA methylation sequencing and analysis services help research institutions around the world to better understand the potential clinical utility of ctDNA as a clinical index in the diagnosis and prognosis of cancer.
- Methylated DNA immunoprecipitation sequencing (MeDIP-Seq): This technology allows cost-effective detection of ctDNA methylation by specific capturing of methylated ctDNA fragments from the genome through 5mC-specific antibodies, combined with high-throughput sequencing technology.
- Bisulfite sequencing (Bis-Seq): Methylated cytosine remains unaffected under bisulfite treatment whereas unmethylated cytosine will be converted to uracil. This technology combines the bisulfite treatment of ctDNA and high-throughput sequencing technology, allowing profiling of ctDNA methylation.
Advantages
- One-stop services from sample preparation to high-quality data delivery
- Specific enrichment of ctDNA fragments using our proprietary ctDNA extraction kit
- Strict QC to ensure accurate data delivery
- Professional and personalized bioinformatic analysis to meet the purposes of different project
Sample Requirements
1) Sample Type:
- Serum, plasma, body fluid, etc.
- Please inquire about other sample types.
2) Sample Size:
- Serum/Plasma: ≥5 mL;
- Body fluids: Please inquire for details.
3) Sample Storage:
- Serum, plasma, and body fluid samples are quick-frozen in liquid nitrogen and stored at -80°C.
- Avoid repeated freezing and thawing during sample storage.
4) Sample Transportation: Dry ice transport.
If you are interested in our services, please feel free to contact us for more details.
Reference
- Luo, H.; et al. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Science Translational Medicine. 2020, 12(524): 7533.
